title: Efficacy of Daily Low-dose Tadalafil for Treating Overactive Bladder: Results of a Randomized, Double-blind, Placebo-controlled Trial.
abstract: OBJECTIVE
  To evaluate the efficacy of daily low-dose tadalafil therapy for overactive bladder (OAB) in women.
  
  
  METHODS
  A total of 96 women with idiopathic OAB from 3 medical centers in the south of Zhejiang Province of China were randomly assigned to treatment with daily low-dose tadalafil (5 mg, n = 48) or placebo (n = 48) for 3 months. The Indevus Urgency Severity Scale, overactive bladder symptom score (Homma et al, 2006), and a 3-day micturition diary with frequency, incontinence, and urgency episodes were recorded and compared before the treatment, every 2 weeks following the treatment, and 3 months after the treatment. Uroflowmetry and transabdominal ultrasound were also conducted following the treatment to determine the maximum flow rate, voided volume, postvoid residual volume, total bladder capacity, and voiding efficiency. The patient's overall rating of improvement in symptoms was assessed as well.
  
  
  RESULTS
  The overactive bladder symptom score significantly decreased, and the frequency, incontinence, and urgency episodes significantly improved in the tadalafil treatment group as compared with the placebo group and baselines at weeks 4, 6, 8, 10, and 12, as well as 3 months posttreatment (P <.05). In addition, voided volume and total bladder capacity obviously increased in the treatment group (P <.05). The Indevus Urgency Severity Scale decreased from week 4 to 3 months posttreatment in the treatment group (P <.05). No changes were found in the maximum flow rate, postvoid residual volume, and voiding efficiency. All adverse symptoms were mild to moderate.
  
  
  CONCLUSIONS
  Daily low-dose tadalafil is a considerable, well-tolerated, and effective treatment for OAB in women.
authors.affiliation: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
authors.forename: Hongde
authors.initials: H
authors.lastname: Chen
authors.affiliation: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Wang
authors.affiliation: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Zhixian
authors.initials: Z
authors.lastname: Yu
authors.affiliation: Department of Urology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Yirong
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Urology, Wencheng County People's Hospital, Wenzhou, Zhejiang, China.
authors.forename: Chaohui
authors.initials: C
authors.lastname: Liu
authors.affiliation: Department of Urology, Yongjia County People's Hospital, Wenzhou, Zhejiang, China.
authors.forename: Shengjie
authors.initials: S
authors.lastname: Dai
authors.affiliation: Laboratory of Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
authors.forename: Bicheng
authors.initials: B
authors.lastname: Chen
authors.affiliation: Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. Electronic address: 4649528@qq.com.
authors.forename: Jiaju
authors.initials: J
authors.lastname: Lv
mesh_terms: D000328:Adult; D002681:China; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D000068581:Tadalafil / Q000627:therapeutic use*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000150:complications / Q000188:drug therapy*; D014554:Urination; D064804:Urological Agents / Q000627:therapeutic use*
chemical_list: D064804:Urological Agents; D000068581:Tadalafil